• The technology described in this briefing is myAIRVO2. It is designed to warm and humidify respiratory gases used for nasal high-flow therapy. This briefing focuses on its potential use in a community setting.

  • The innovative aspects are that myAIRVO2 is designed to allow the delivery of nasal high-flow therapy in a community setting. It is also designed to allow clinicians to titrate flow and oxygen independently from one another and does not need a sealed interface.

  • The intended place in therapy would be as well as standard management in the home or long-term care environment for people with chronic obstructive pulmonary disease (COPD) having nasal high-flow oxygen therapy.

  • The main points from the evidence summarised in this briefing are from 5 studies, 1 randomised controlled trial and 4 randomised crossover trials including a total of 232 adults. They show that myAIRVO2 is at least as effective as non-humidified and unwarmed gases in patients with COPD and has the potential to reduce hospital admissions.

  • Key uncertainties around the evidence relate to the lack of follow‑up to show the long-term positive effects of myAIRVO2 and the generalisability to UK NHS practice. There are also uncertainties around which patient group nasal high-flow therapy would most benefit in a community setting and if it should be used with or instead of current treatments.

  • The cost of myAIRVO2 is £2,475 per unit (excluding VAT). The overall resource impact is uncertain because there is no published evidence assessing the resource consequences of myAIRVO2 in a community setting. More information on this would be helpful.